About Us
Video
Learn more about DermTech’s EGIR™ Technology »
Melanoma Facts
- By 2010, current estimates indicate 1:50 people will be diagnosed with melanoma during their lifetime.
- Melanoma is the most common cancer in women aged 25-29.
- If melanoma is treated before it spreads, it is 99% curable.
About DermTech
DermTech International is a La Jolla-based biotechnology company specializing in the development and validation of molecular tests using specimens derived from the skin. We have developed a proprietary, non-invasive technique for sampling the surface layers of the skin in order to generate individual genetic profiles for commercial applications in the medical diagnostic, personalized medicine and pharmaceutical R&D arenas.
Learn More About DermTech »
EGIR™ Technology
- Patented handheld device obtains cells from the upper layer of skin using custom adhesive tape.
- Collected tape is sent to lab. RNA is extracted and analyzed using molecular biology tools.
MelDTect™ Test
- Patented 19-gene biomarker is used to objectively detect melanoma.
- Clear results available to dermatologist in 3-5 days.